# Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

> **NCT05363800** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 198 (estimated)

## Conditions studied

- Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

## Interventions

- **DRUG:** HRS-3738

## Key facts

- **NCT ID:** NCT05363800
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-17
- **Primary completion:** 2024-10-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05363800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05363800, "Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT05363800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*